Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang 315800, China.
Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang 315211, China.
Mar Drugs. 2019 Aug 23;17(9):493. doi: 10.3390/md17090493.
Protein kinases are validated drug targets for a number of therapeutic areas, as kinase deregulation is known to play an essential role in many disease states. Many investigated protein kinase inhibitors are natural product small molecules or their derivatives. Many marine-derived natural products from various marine sources, such as bacteria and cyanobacteria, fungi, animals, algae, soft corals, sponges, etc. have been found to have potent kinase inhibitory activity, or desirable pharmacophores for further development. This review covers the new compounds reported from the beginning of 2014 through the middle of 2019 as having been isolated from marine organisms and having potential therapeutic applications due to kinase inhibitory and associated bioactivities. Moreover, some existing clinical drugs based on marine-derived natural product scaffolds are also discussed.
蛋白激酶是许多治疗领域的经过验证的药物靶点，因为激酶失调已知在许多疾病状态中起着至关重要的作用。许多经过研究的蛋白激酶抑制剂是天然产物小分子或其衍生物。已经发现来自各种海洋来源的许多海洋衍生天然产物，例如细菌和蓝藻、真菌、动物、藻类、软珊瑚、海绵等，具有有效的激酶抑制活性，或者具有进一步开发的理想药效团。本综述涵盖了自 2014 年初至 2019 年年中从海洋生物中分离出来的具有潜在治疗应用的新型化合物，这些化合物因具有激酶抑制和相关的生物活性而被报道。此外，还讨论了一些基于海洋衍生天然产物支架的现有临床药物。
